natgillin/translations-raw huggingface dataset:
Da brugen af faktor IX-komplekskoncentrater historisk set har været forbundet med udvikling af thrombo-emboliske komplikationer, og risikoen er højere for præparater af en mindre renhedsgrad, kan brugen af faktor IX-holdige produkter muligvis være skadelige hos patienter med tegn på fibrinolyse og hos patienter med dissemineret intravaskulær koagulering (DIC).
Since the use of factor IX complex concentrates has historically been associated with the development of thromboembolic complications, the risk being higher in low purity preparations, the use of factor IX-containing products may be potentially hazardous in patients with signs of fibrinolysis and in patients with disseminated intravascular coagulation (DIC).
Da budesonid og formoterol primært udskilles via hepatisk metabolisme, kan en forøget eksponering forventes hos patienter med alvorlig levercirrhose.
As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis.
Da Budesonid/Formoterol Teva Pharma B.V. indeholder både budesonid og formoterol, kan det samme bivirkningsmønster, som er indberettet for disse stoffer, forekomme.
Since Budesonide/Formoterol Teva Pharma B.V. contains both budesonide and formoterol, the same pattern of adverse reactions as reported for these substances may occur.
Da Busilvex i kombination med fludarabin er blevet anvendt i klinisk praksis i mange år, blev der fremlagt data fra 7 undersøgelser (med 731 patienter), hvori der blev set nærmere på virkningen af Busilvex og fludarabin som konditionerende behandling med »reduceret intensitet«.
Since Busilvex in combination with fludarabine has been used in clinical practice for many years, data from 7 studies (involving 731 patients) which looked at the effectiveness of Busilvex and fludarabine as ‘reduced-intensity’ conditioning treatment were presented.
Da Busulfan Fresenius Kabi gives ved infusion og indeholder samme aktive stof som referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Busulfan Fresenius Kabi is given by infusion and contains the same active substance as the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da både passive og aktive processer er involveret, er der et potentiale for konkurrence om elimination med andre renalt udskilte aktive stoffer.
As both passive and active processes are involved, there is the potential for competition for elimination with other renally eliminated active substances.
Da C1-hæmmer er et endogent humant plasmaprotein, metaboliseres det ikke af cytokrom P450 iso-enzymer, udskillelse eller giver de farmakokinetiske lægemiddel-lægemiddelinteraktioner, som mange lavmolekylære stoffer udviser.
Because C1 inhibitor is an endogenous human plasma protein, it is not subject to metabolism by Cytochrome P450 iso-enzymes, excretion, or pharmacokinetic drug-drug interactions exhibited by many low molecular weight compounds.
Da canakinumab binder sig til IL-1 beta med lignende affinitet i egernaber (C. jacchus) og mennesker, er canakinumabs sikkerhed blevet undersøgt hos egernaber.
Since canakinumab binds to marmoset (C. jacchus) and human IL-1 beta with a similar affinity, the safety of canakinumab has been studied in the marmoset.
Da Capecitabine Accord er bioækvivalent med referencelægemidlet, antages det at have de samme fordele og risici som referencelægemidlet.
Because Capecitabine Accord is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da Capecitabine Medac indeholder det samme aktive stof som referencelægemidlet, anses dets fordele og risici for at være de samme som for referencelægemidlet.
Because Capecitabine Medac contains the same active substance as its reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da Capecitabine SUN er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Capecitabine SUN is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da Capecitabine Teva er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Capecitabine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da Caspofungin Accord er et generisk lægemiddel, antages det at have de samme fordele og risici som referencelægemidlet.
Because Caspofungin Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da Ciambra er et generisk lægemiddel, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Ciambra is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da ciclosporin er bundet til RBC’er, er der imidlertid en mulighed for interaktion med andre lægemidler.
However, since ciclosporin is bound by red blood cells there is potential for interactions with other medicinal products.
Da Cinacalcet Mylan er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Cinacalcet Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da clearance af Kyprolis-koncentrationer ved dialyse ikke er undersøgt, skal lægemidlet administreres efter dialysen (se pkt.
Since dialysis clearance of Kyprolis concentrations has not been studied, the medicinal product should be administered after the dialysis procedure (see section 5.2).
Da clofarabin nedsætter dannelsen af blodlegemer i knoglemarven, har du en øget risiko for at få en infektion;
if you get a fever or high temperature – because clofarabine reduces the number of blood cells made in the bone marrow, you may be more likely to catch infections;
Da Clopidogrel HCS er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel HCS is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as those of the reference medicine’s.
Da Clopidogrel Krka er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel Krka is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Da Clopidogrel ratiopharm er et generisk lægemiddel, har patientundersøgelserne været begrænset til at påvise, at det er bioækvivalent med referencelægemidlet, Plavix.
Because Clopidogrel ratiopharm is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Da Clopidogrel ratiopharm er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da Clopidogrel Ratiopharm GmbH er et generisk lægemiddel, der er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel ratiopharm GmbH is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine’s.
Da Clopidogrel TAD er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel TAD is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Da Clopidogrel Teva Pharma B.V. er et generisk lægemiddel, har patientundersøgelserne været begrænset til at påvise, at det er bioækvivalent med referencelægemidlet Plavix.
Because Clopidogrel Teva Pharma B.V. is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Da Clopidogrel Teva Pharma B.V. er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel Teva Pharma B.V. is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Da Clopidogrel Teva Pharma er et generisk lægemiddel, har patientundersøgelserne været begrænset til at påvise, at det er bioækvivalent med referencelægemidlet Plavix.
Because Clopidogrel Teva Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Da Clopidogrel Teva Pharma er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Clopidogrel Teva Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine’s.
Da Co- lobreathe er et inhalationspulver, forventes det at være behageligere for patienterne end en nebulisa- tor.
Colobreathe, as a powder for inhalation, is expected to be more convenient for patients than nebulisers.
Da cobicistat er til stede kan samtidig administration af Genvoya føre til øgede plasmakoncentrationer af dette lægemiddel, hvilket er forbundet med risikoen for alvorlige og/eller livstruende bivirkninger.
Due to the presence of cobicistat, co-administration with Genvoya may result in increased plasma concentrations of this medicinal product, which is associated with the potential for serious or life- threatening adverse reactions.
Da Combivir indeholder zidovudin, bør det ikke anvendes til patienter med et lavt neutrofiltal (en type hvide blodlegemer) eller anæmi (lavt antal røde blodlegemer).
Because it contains zidovudine, Combivir must not be used by patients with low neutrophil counts (a type of white blood cell) or anaemia (low red blood cell counts).
Da crizotinib i stort omfang metaboliseres i leveren, er det sandsynligt, at nedsat leverfunktion øger plasma-crizotinib.
As crizotinib is extensively metabolized in the liver, hepatic impairment is likely to increase plasma crizotinib concentrations.
Da CYP3A
CYP3A by
Da CYP3A
Due to induction of
Da CYP3A
Due to inhibition of
da da da dag g 1 g 2 g 3 4
Day Day Day Day 1 2 3 4
Da dabigatran hovedsageligt udskilles via nyrerne skal tilstrækkelig diurese opretholdes.
Since dabigatran is excreted predominantly by the renal route adequate diuresis must be maintained.
Da DARZALEX ikke indeholder konserveringsmiddel, skal den fremstillede infusionsvæske administreres inden for 15 timer (inklusive infusionstid), opbevaret ved stuetemperatur (15- 25 °C) og almindelig belysning.
Since DARZALEX does not contain a preservative, diluted solutions should be administered within 15 hours (including infusion time) at room temperature (15°C - 25°C) and in room light.
Da Dasselta er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
Because Dasselta is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Da de beregnede værdier for en stor dels vedkommende er en funktion af studiets varighed, den anvendte dosis og analysens følsomhed, er den sande terminale halveringstid sandsynligvis væsentlig længere, ligesom hos andre bisphosphonater.
As the values calculated are largely a function of the duration of study, the dose used, and assay sensitivity, the true terminal half-life is likely to be substantially longer, in common with other bisphosphonates.
Da de embryonale/føtale udviklingsundersøgelser blev udført på raske drægtige dyr, og da sygdom (såsom diabetes) kan påvirke permeabiliteten af placenta over for et Fab-fragment, skal studiet fortolkes med forsigtighed.
As the embryo- foetal development investigations were performed in healthy pregnant animals and disease (such as diabetes) may modify the permeability of the placenta towards a Fab fragment, the study should be interpreted with caution.
Da de farmakokinetiske egenskaber af Levemir ikke er blevet omfattende undersøgt hos disse patientgrupper, anbefales det at monitorere plasmaglucoseniveauet nøje.
As the pharmacokinetics of Levemir has not been studied extensively in these populations, it is advised to monitor plasma glucose closely in these populations.
Da de fleste bivirkninger kan forekomme tidligt i behandlingsforløbet, skal lægen evaluere patienten tæt i de første otte behandlingsuger for at vurdere, om dosisændring er nødvendig.
As most events can occur early in the course of treatment, the physician should evaluate the patient closely during the first eight weeks of treatment to determine if dose modifications are warranted.
Da deferipron nedbrydes i leveren skal der ligeledes udvises forsigtighed hos patienter med leverinsufficiens.
Similarly, as deferiprone is metabolised in the liver, caution must be exercised in patients with hepatic dysfunction.
Da Defitelio blev godkendt under særlige omstændigheder, skal den virksomhed, der markedsfører lægemidlet, oprette et patientregister for at fremskaffe yderligere data om lægemidlets langsigtede sikkerhed, de helbredsmæssige udfald og den måde, som lægemidlet anvendes på i praksis.
Since Defitelio has been approved under exceptional circumstances, the company that markets the medicine is required to set up a patient registry to provide further data on long-term safety, health outcomes, and the way the medicine is used in practice.
Da den aktive guanin- analog ophobes i T-cellerne og forbliver længere i disse celler, bremser Atriance vækst og formering af de celler, der optræder ved T-ALL og T-LBL.
Because the guanine analogue accumulates in T- cells and lasts longer in these cells, Atriance slows down the growth and multiplication of the cells involved in T-ALL and T-LBL.
Da den aktive metabolit dannes af CYP450-enzymer, hvoraf nogle er polymorfe eller genstand for hæmning af andre lægemidler, vil ikke alle patienter opnå passende trombocytaggregation..
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition.
Da den anbefalede dolutegravirdosis er
Since the recommended dose of
Da den anbefalede dolutegravirdosis er 50 mg 2 gange daglig ved administration sammen med perikon, anbefales DTG/ABC/3TC FDC ikke.
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with St. John’s wort, DTG/ABC/3TC FDC is not recommended.
Da den anbefalede dolutegravirdosis er 50 mg to gange daglig ved administration sammen med carbamazepin, anbefales DTG/ABC/3 TC FDC ikke til patienter, som tager carbamazepin.
dolutegravir is 50 mg twice daily when co-administered with carbamazepine, DTG/ABC/3TC FDC is not recommended for patients taking carbamazepine.
Da den anbefalede dolutegravirdosis er 50 mg to gange daglig, når det administreres sammen med etravirin (uden boostede proteasehæmmere), efavirenz, nevirapin, rifampicin, tipranavir/ritonavir, carbamazepin, phenytoin, phenobarbital og perikon, anbefales Triumeq ikke til patienter, der tager disse lægemidler (se pkt.
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with etravirine (without boosted protease inhibitors), efavirenz, nevirapine, rifampicin, tipranavir/ritonavir, carbamazepine, phenytoin, phenobarbital and St. John’s wort, the use of Triumeq is not recommended for patients taking these medicines (see section 4.5).
Da den anbefalede dosis af dolutegravir er 50 mg to gange daglig, når det administreres samtidigt med tipranavir/ritonavir, anbefales samtidig administration af tipranavir/ritonavir og Triumeq ikke.
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with tipranavir/ritonavir, the co- administration of tipranavir/ritonavir with Triumeq is not recommended.
Da den effektive dosis er 4,35 mSv, når den maksimalt anbefalede aktivitet på 185 MBq indgives, forventes det, at sandsynligheden for, at disse bivirkninger forekommer, er lav.
As the effective dose is 4.35 mSv when the maximal recommended activity of 185 MBq is administered these adverse events are expected to occur with a low probability.
Da den farmakokinetiske variation er stor og maropitant akkumuleres i kroppen efter en daglig, gentagent dosis, kan lavere dosis end den anbefalede være tilstrækkelig hos nogle hunde, når dosis skal gentages.
As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.
Da den indgivne mængde afhænger af legemsvægten, vil lægen være nødt til løbende at tilpasse dosis efter patientens vægt, navnlig hos børn i voksealderen.
As the amount given depends on the individual’s bodyweight, the doctor will need to adjust the dose as patient’s weight changes, particularly in growing children.
Da den individuelle følsomhed er forskellig, kan nogle patienter opleve døsighed eller andre CNS- relaterede symptomer især i begyndelsen af behandlingen eller ved øgning af dosis.
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase.
Da den kardiovaskulære risiko ved brug af specifikke cyklooxygenase-2 (COX-2)-hæmmere kan øges med dosis og behandlingsvarighed, bør den kortest mulige behandlingsvarighed og den laveste effektive daglige dosis anvendes.
As the cardiovascular risk of cyclooxygenase-2 (COX-2) specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Da den mekanisme, hvormed ataluren øger intravenøse aminoglykosiders nefrotoksicitet ikke er kendt, frarådes samtidig brug af andre nefrotoksiske lægemidler med ataluren.
Since the mechanism by which ataluren increases nephrotoxicity of intravenous aminoglycosides is not known, concomitant use of other nephrotoxic medicinal products with ataluren is not recommended.
Da den opdaterede analyse kun angives til beskrivende formål, er det kun p-værdien, der ikke opgives. b Hazard ratio (Xofigo over placebo) < 1 favoriserer Xofigo.
As the updated analysis is provided for descriptive purposes only, a p-value is not provided. b Hazard ratio (Xofigo over placebo) < 1 favours Xofigo.
Da den potentielle risiko for mennesker er ukendt, skal kvinder i den fertile alder anvende sikker antikonception.
As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential.
Da den primære behandlingseffekt af Starlix er at reducere prandial glukose (som bidrager til HbA1c), kan den terapeutiske reaktion på Starlix også måles med 1–2 timer postprandial glukose.
Since the primary therapeutic effect of Starlix is to reduce mealtime glucose, (a contributor to HbA1c), the therapeutic response to Starlix may also be monitored with 1–2 hour post-meal glucose.
Da den primære behandlingseffekt af Trazec er at reducere prandial glukose (som bidrager til HbA1c), kan den terapeutiske reaktion på Trazec også måles med 1–2 timer postprandial glukose.
Since the primary therapeutic effect of Trazec is to reduce mealtime glucose, (a contributor to HbA1c), the therapeutic response to Trazec may also be monitored with 1–2 hour post-meal glucose.
Da den præcise patogenese ikke er kendt, kan der kun anbefales støttende behandling.
As the precise pathogenesis is unknown, only supportive measures can be recommended.
Da den systemiske eksponering er lav ved behandling med tacrolimussalve, er den kraftige plasmabinding af tacrolimus (> 98,8%) næppe klinisk relevant.
As systemic exposure is low with tacrolimus ointment, the high binding of tacrolimus (> 98.8%) to plasma proteins is considered not to be clinically relevant.
Da den systemiske eksponering for trabectedin sandsynligvis vil blive øget på grund af den nedsatte leverfunktion, og risikoen for levertoksicitet kan blive øget, skal patienter med klinisk relevante leversygdomme såsom aktiv kronisk hepatitis monitoreres nøje og dosis om nødvendigt justeres.
Since systemic exposure to trabectedin is probably increased due to hepatic impairment and therefore the risk of hepatotoxicity might be increased, patients with clinically relevant liver diseases, such as active chronic hepatitis, must be closely monitored and the dose adjusted if needed.
Da den systemiske eksponering hos ikke-gravide kvinder er ubetydelig efter behandling med Nevanac, kan risikoen under graviditet anses for lav.
Since the systemic exposure in non-pregnant women is negligible after treatment with NEVANAC, the risk during pregnancy could be considered low.
Da denne hændelse hyppigt blev rapporteret hos patienter, der ikke har blodtype 0, og som får høje doser for ikke-PID-indikationer, tilrådes øget årvågenhed.
As this event was commonly reported in non-0 blood group patients receiving high doses for non-PID indications, increased vigilance is recommended.
Da denne vaccineform indeholder spormængder af gentamicin og indeholder tetracyclin som biomarkør, kan hypersensitivitet lejlighedsvist forekomme hos husdyr, som ved et uheld indtager lokkemaden.
As this vaccine presentation contains traces of gentamicin and contains tetracycline as biomarker, occasional hypersensitivity reactions may be observed in domestic animals that have accidentally ingested the bait.
Da der blev rapporteret hypertension ved samtidig brug af systemiske kortikosteroider hos visse patienter i kliniske forsøg, anbefales overvågning af systolisk og diastolisk blodtryk i hvile hver 6. måned hos patienter med nmDMD, der får ataluren samtidig med kortikosteroider, eller hyppigere efter behov baseret på patientens kliniske status.
Because hypertension with use of concomitant systemic corticosteroids was reported for some patients in clinical trials, it is recommended that resting systolic and diastolic blood pressure be monitored every 6 months in nmDMD patients receiving ataluren concomitantly with corticosteriods, or more frequently as needed based on the patient’s clinical status.
Da der derfor ikke kan gives doseringsanbefa- linger for kombinationen af Agenerase oral opløsning og lave doser af retronavir skal kombinationen undgås til denne patientgruppe.
Additionally, as no dosing recommendations can be made regarding the concomitant use of Agenerase oral solution and low dose ritonavir, the use of this combination must be avoided in these patient populations.
Da der er begrænsede data for patienter med nedsat nyrefunktion, skal Vedrop administreres med forsigtighed og under tæt monitorering af nyrefunktionen hos patienter med nyreinsufficiens, f.eks. dehydrerede patienter. (se pkt.4.2)
As data on patients with renal impairment are limited, Vedrop should be administered with caution and under close monitoring of the renal function in patients with renal impairment e.g. dehydrated patients (see section 4.2).
Da der er begrænset behandling af behandling med børn, kan dette ikke anbefales.
The experience in children is limited and treatment is therefore not recommended.